AR062900A1 - Derivados de isoquinolina y de quinazolina utiles como inhibidores de quinasa rho - Google Patents
Derivados de isoquinolina y de quinazolina utiles como inhibidores de quinasa rhoInfo
- Publication number
- AR062900A1 AR062900A1 ARP070104139A ARP070104139A AR062900A1 AR 062900 A1 AR062900 A1 AR 062900A1 AR P070104139 A ARP070104139 A AR P070104139A AR P070104139 A ARP070104139 A AR P070104139A AR 062900 A1 AR062900 A1 AR 062900A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- cycloalkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
Para tratar diversas enfermedades y trastornos en los que intervenga o sean mantenidos por la actividad de cinasa Rho, entre ellos enfermedades cardiovasculares, composiciones farmacéuticas que comprenden tales compuestos, métodos para emplear tales compuestos y procedimientos para preparar tales compuestos. Reivindicacion 5: Un compuesto de formula (1) en donde R1 se elige entre cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6 , haloalquilo C1-6, aminoalquilo C1-6, hidroxialquilo C1-6, arilo, aril-alquilo C1-6, heteroarilo, heteroaril-alquilo C1-6, heterociclilo, -alquilo C1-3-O-arilo, -C(H)0-1-(alquil C1-6)1-2-arilo, -CH(OH)-arilo, -C(OH)(CH3)-arilo, -CH[OC(O)-(alquil C1-6)]-arilo, -CH2OCH2-arilo, -CH2OC(O)-(alquilo C1-6), - (CH2)1-3S(O)0-2-arilo, -(CH2)1-2S(O)0-2-(alquilo C1-6, -(CH2)1-3CO2-(alquilo C1-6, -(CH2)1-3NH(alquilo C1-6, -(CH2)1-3NH(alquil C1-6)-(cicloalquilo C3-8), -(CH2)1-2-CN y -CH(R3)N(R4)(R5) en donde: R3 se elige entre H, arilo, alquilo C1-6, -(CH2)1-3- arilo y - (CH2)1-3 heteroarilo; R4 se elige entre H, alquilo C1-6, cicloalquilo C3-12, (cicloalquil C3-7)-(alquilo C1-6), arilo, aril-(CH2)1-3, heteroaril-(CH2)1-3, (alquil C1-3)-O(CH2)1-3, tetrahidropiran-4-ilmetilo y (alquil C1-3)2N(CH2)2-4-; y R5 se elige entre H y alquilo C1-6 o bien R4 y R5 junto con el átomo de nitrogeno al cual están conectados pueden formar un grupo heterociclilo; en donde cada grupo arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilalquilo, cicloalquilo y heterociclilo está opcionalmente sustituido con 1-3 grupos seleccionados entre halogeno, alcoxi C1-6, cicloalquilo C3-8, alquilo C1-6, -CN, NO2, -OH, oxo, -CF3, -OCF3, -(alquil C0-3)-CO2H, (alquil C1-6-CO2-, (alquil C1-6)-sulfonil-(alquilo C0-3)-, - SO2-(alquil C1-6)-NR6R7, -(alquil C0-3)-SO2NR6R7, -(alquil C0-3)-C(O)NR6R7, arilo, heteroarilo, heteroaril-(alquilo C1-3), heterociclilo, heterociclil-SO2-, aril-(alquilo C1-3), ariloxi, ariltio y C0-3NR6R7; en donde cada grupo arilo y heteroarilo está opcionalmente sustituido con 1-3 grupos seleccionados entre halogeno, alcoxi C1-6, alquilo C1-6, -CN, -NO2, -OH, -CF3, -OCF3, -C(O)NR8R9, -SO2NR8R9, -SO2Me y amino opcionalmente sustituido con uno o dos grupos alquilo C1-6 o un grupo C(O)(alquilo C1-6); R2 se elige entre H, halogeno, alcoxi C1-6, -CN, -CF3 y alquilo C1-6; R6 y R7 se seleccionan, de manera independiente, entre H, alquilo C1-6, -C(O)-(alquilo C1-6) y -(alquil C1-6)NH2; o bien R6 y R7, junto con el átomo de nitrogeno al cual están conectados, pueden formar un anillo de piperazina, piperidina o pirrolidina; R8 y R9 se seleccionan, de manera independiente, entre H y metilo; R10 se selecciona entre H, Cl y F; X se elige entre C y N; e Y se elige entre - NHC(O)-, -NHC(O)NH- y -NHC(O)O-; o un tautomero o una sal del compuesto de formula (1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82628406P | 2006-09-20 | 2006-09-20 | |
US86448406P | 2006-11-06 | 2006-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062900A1 true AR062900A1 (es) | 2008-12-10 |
Family
ID=38740290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104139A AR062900A1 (es) | 2006-09-20 | 2007-09-19 | Derivados de isoquinolina y de quinazolina utiles como inhibidores de quinasa rho |
Country Status (9)
Country | Link |
---|---|
US (5) | US8809326B2 (es) |
EP (2) | EP2526948A1 (es) |
JP (1) | JP5235887B2 (es) |
AR (1) | AR062900A1 (es) |
CA (1) | CA2664335C (es) |
CL (1) | CL2007002686A1 (es) |
ES (1) | ES2729424T3 (es) |
TW (1) | TW200819133A (es) |
WO (1) | WO2008036540A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007008942A2 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
WO2007008926A1 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
EP2066619A2 (en) * | 2006-11-02 | 2009-06-10 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
NZ590067A (en) * | 2008-06-24 | 2012-09-28 | Sanofi Aventis | Bi-and polycyclic substituted isoquinoline and isoquinolinone derivatives as rho kinase inhibitors |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US8653099B2 (en) * | 2008-08-19 | 2014-02-18 | Janssen Pharmaceutica | Cold menthol receptor antagonists |
CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
FR2956816B1 (fr) * | 2010-03-01 | 2012-05-18 | Univ Joseph Fourier | Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese |
US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
JP5769326B2 (ja) | 2010-10-19 | 2015-08-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rhoキナーゼ阻害薬 |
CN103864684A (zh) * | 2012-12-07 | 2014-06-18 | 天津科技大学 | 一种新颖的3,4-二氢-1(2h)异喹啉类衍生物的合成与抗肿瘤药物的应用 |
EP3252049A1 (en) | 2013-01-18 | 2017-12-06 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
EP3461484B9 (en) | 2013-03-15 | 2021-06-09 | Aerie Pharmaceuticals, Inc. | Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders |
US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
ES2838573T3 (es) | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
EA201790434A1 (ru) | 2014-08-22 | 2017-07-31 | Окленд Юнисервисиз Лимитед | Модуляторы каналов |
JP6832946B2 (ja) | 2015-11-17 | 2021-02-24 | アエリエ ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤およびその中間体の調製方法 |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
ES2829550T3 (es) | 2016-07-07 | 2021-06-01 | Bristol Myers Squibb Co | Ureas cíclicas espiro-condensadas como inhibidores de ROCK |
BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
ES2951212T3 (es) | 2017-07-12 | 2023-10-18 | Bristol Myers Squibb Co | Fenilacetamidas como inhibidores de ROCK |
TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
JP7313331B2 (ja) | 2017-07-12 | 2023-07-24 | ブリストル-マイヤーズ スクイブ カンパニー | Rock阻害剤としてのスピロヘプタニルヒダントイン |
JP7234201B2 (ja) | 2017-07-12 | 2023-03-07 | ブリストル-マイヤーズ スクイブ カンパニー | 心不全の治療のためのrockの5員アミノヘテロ環および5,6-または6,6員二環式アミノヘテロ環の阻害剤 |
KR102568375B1 (ko) * | 2018-03-29 | 2023-08-18 | 김미희 | RhoA 억제제 및 이의 용도 |
EP3843845A4 (en) | 2018-08-29 | 2022-05-11 | University Of Massachusetts | INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA |
AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CN115572282A (zh) * | 2021-07-05 | 2023-01-06 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2623228C3 (de) | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
JPS5587771A (en) | 1978-12-27 | 1980-07-02 | Teikoku Hormone Mfg Co Ltd | 1-phenylisoquinoline derivative |
US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
JPS5993054A (ja) | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
DK8386A (da) | 1986-01-15 | 1987-07-09 | Tpo Pharmachim | Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
JPH01139528A (ja) | 1987-11-24 | 1989-06-01 | Showa Denko Kk | 抗潰瘍剤 |
EP0389995B1 (en) | 1989-03-28 | 1995-05-31 | Nisshin Flour Milling Co., Ltd. | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension |
KR920008026A (ko) * | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
JPH07504429A (ja) | 1992-03-12 | 1995-05-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5HT↓1cアンタゴニストとしてのインドール誘導体 |
DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6586425B2 (en) | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
US5798380A (en) | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
US5891646A (en) | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
US6720175B1 (en) | 1998-08-18 | 2004-04-13 | The Johns Hopkins University School Of Medicine | Nucleic acid molecule encoding homer 1B protein |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
CN101898982B (zh) | 1999-11-26 | 2012-07-04 | 盐野义制药株式会社 | Npy y5拮抗剂 |
AU776933B2 (en) | 1999-12-28 | 2004-09-23 | Eisai R&D Management Co., Ltd. | Heterocyclic compounds having sulfonamide groups |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
DE60141889D1 (de) | 2000-02-03 | 2010-06-02 | Eisai R&D Man Co Ltd | Inhibitoren der integrinexpression |
US6410566B1 (en) | 2000-05-16 | 2002-06-25 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
US7312358B2 (en) | 2000-10-17 | 2007-12-25 | Laboratoires Serono Sa | Pharmaceutically active sulfanilide derivatives |
US7163800B2 (en) | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
EP1387680A4 (en) | 2001-03-05 | 2010-01-13 | Transtech Pharma Inc | AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE |
EP1379505B1 (en) | 2001-04-20 | 2007-02-28 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
AU2003202263A1 (en) | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
US20040180889A1 (en) | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
ES2373875T3 (es) | 2002-03-05 | 2012-02-09 | Transtech Pharma, Inc. | Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage. |
US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
DE60325719D1 (de) | 2002-05-13 | 2009-02-26 | Molecular Devices Corp | Konstitutiv translozierende zelllinie |
ATE546143T1 (de) | 2002-08-29 | 2012-03-15 | Santen Pharmaceutical Co Ltd | Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen |
JPWO2004022753A1 (ja) | 2002-08-30 | 2005-12-22 | アンジェスMg株式会社 | アクチン関連新規細胞骨格タンパク質lacs |
US7615564B2 (en) | 2002-09-12 | 2009-11-10 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
CA2526387A1 (en) | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
EP1689393A4 (en) | 2003-10-06 | 2008-12-17 | Glaxo Group Ltd | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS |
JP2007008816A (ja) * | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
JP4110324B2 (ja) | 2003-10-15 | 2008-07-02 | 宇部興産株式会社 | 新規インダゾール誘導体 |
SE0400284D0 (sv) | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
JP2005227441A (ja) | 2004-02-12 | 2005-08-25 | Konica Minolta Medical & Graphic Inc | 光熱写真画像形成材料 |
EP1718638A4 (en) | 2004-02-20 | 2009-04-22 | Smithkline Beecham Corp | NEW COMPOUNDS |
US20080096238A1 (en) | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
DE102004017438A1 (de) | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
JP2008503492A (ja) | 2004-06-17 | 2008-02-07 | スミスクライン・ビーチャム・コーポレイション | Rho−キナーゼの新規阻害剤 |
WO2006041119A1 (ja) | 2004-10-13 | 2006-04-20 | Eisai R & D Management Co., Ltd. | ヒドラジド誘導体 |
UY29198A1 (es) * | 2004-11-09 | 2006-05-31 | Cancer Rec Tech Ltd | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones |
GB0425026D0 (en) | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
WO2006062982A2 (en) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
US20080207677A1 (en) | 2004-12-31 | 2008-08-28 | Gpc Biotech Ag | Napthyridine Compounds As Rock Inhibitors |
WO2006076706A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
US20090005321A1 (en) | 2005-02-09 | 2009-01-01 | Microbia, Inc. | Phenylazetidinone Derivatives |
AU2006249596A1 (en) | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing 6-alkylaminoquinoline derivatives |
WO2007008926A1 (en) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
WO2007008942A2 (en) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
EP2111863B1 (en) | 2005-10-26 | 2012-03-28 | Asahi Kasei Pharma Corporation | Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
US7655662B2 (en) | 2005-12-22 | 2010-02-02 | Alcon Research, Ltd. | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure |
AR057252A1 (es) | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
CA2633624C (en) | 2005-12-30 | 2013-11-19 | Novartis Ag | 3,5-substituted piperidine compounds as renin inhibitors |
JP5476559B2 (ja) | 2006-02-10 | 2014-04-23 | 国立大学法人九州大学 | リン酸化酵素の新規基質ポリペプチド |
EP1991531A1 (en) | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
JP2007246466A (ja) | 2006-03-17 | 2007-09-27 | Osaka Univ | 中枢神経損傷に対する嗅粘膜移植にRhoキナーゼ阻害剤を用いた神経機能再建法 |
TW200815398A (en) | 2006-06-08 | 2008-04-01 | Ube Industries | A novel indazole derivative having spirocyclic structure in the side chain |
US20080021217A1 (en) | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
US20090318485A1 (en) | 2006-07-20 | 2009-12-24 | Kalypsys, Inc. | Novel inhibitors of rho kinase |
CA2659687A1 (en) | 2006-07-31 | 2008-02-07 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparation containing amide compound |
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
WO2008054599A2 (en) | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
WO2008049000A2 (en) | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
WO2008049919A2 (en) | 2006-10-26 | 2008-05-02 | Devgen N.V. | Rho kinase inhibitors |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
WO2008079945A2 (en) | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
CN101611012B (zh) | 2006-12-27 | 2012-11-14 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹啉衍生物 |
CA2673921C (en) | 2006-12-27 | 2015-10-20 | Sanofi-Aventis | New substituted isoquinoline and isoquinolinone derivatives |
AU2007338412B2 (en) | 2006-12-27 | 2013-03-14 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
CA2673918C (en) | 2006-12-27 | 2015-02-17 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
NZ577980A (en) | 2006-12-27 | 2012-01-12 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
PT2125744E (pt) | 2006-12-27 | 2011-07-01 | Sanofi Aventis | Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina |
WO2008077550A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
WO2008124665A1 (en) | 2007-04-10 | 2008-10-16 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
CN103396409B (zh) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
TW201729813A (zh) | 2011-02-04 | 2017-09-01 | Kowa Co Ltd | 青光眼預防或治療之藥物療法 |
EP3461484B9 (en) | 2013-03-15 | 2021-06-09 | Aerie Pharmaceuticals, Inc. | Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders |
WO2014143201A1 (en) | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for noribogaine treatment of addiction in patients on methadone |
AU2015289044A1 (en) | 2014-07-17 | 2016-12-08 | Cancer Research Technology Limited | Novel naphthryidines and isoquinolines and their use as CDK8/19 inhibitors |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
JP6832946B2 (ja) | 2015-11-17 | 2021-02-24 | アエリエ ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤およびその中間体の調製方法 |
-
2007
- 2007-09-13 CA CA2664335A patent/CA2664335C/en active Active
- 2007-09-13 EP EP12003567A patent/EP2526948A1/en not_active Withdrawn
- 2007-09-13 ES ES07814835T patent/ES2729424T3/es active Active
- 2007-09-13 EP EP07814835.0A patent/EP2068878B1/en active Active
- 2007-09-13 WO PCT/US2007/078343 patent/WO2008036540A2/en active Application Filing
- 2007-09-13 JP JP2009529306A patent/JP5235887B2/ja not_active Expired - Fee Related
- 2007-09-14 CL CL200702686A patent/CL2007002686A1/es unknown
- 2007-09-18 US US11/856,740 patent/US8809326B2/en active Active
- 2007-09-19 AR ARP070104139A patent/AR062900A1/es not_active Application Discontinuation
- 2007-09-19 TW TW096134934A patent/TW200819133A/zh unknown
-
2014
- 2014-08-18 US US14/461,597 patent/US20140357652A1/en not_active Abandoned
-
2015
- 2015-06-30 US US14/754,787 patent/US20150297581A1/en not_active Abandoned
-
2016
- 2016-04-29 US US15/142,448 patent/US20160243102A1/en not_active Abandoned
-
2017
- 2017-12-29 US US15/858,995 patent/US10624882B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW200819133A (en) | 2008-05-01 |
CA2664335C (en) | 2014-12-02 |
EP2526948A1 (en) | 2012-11-28 |
US20140357652A1 (en) | 2014-12-04 |
CA2664335A1 (en) | 2008-03-27 |
US20180344723A1 (en) | 2018-12-06 |
EP2068878A2 (en) | 2009-06-17 |
JP5235887B2 (ja) | 2013-07-10 |
EP2068878B1 (en) | 2019-04-10 |
WO2008036540A2 (en) | 2008-03-27 |
JP2010504342A (ja) | 2010-02-12 |
US20160243102A1 (en) | 2016-08-25 |
US8809326B2 (en) | 2014-08-19 |
ES2729424T3 (es) | 2019-11-04 |
US20150297581A1 (en) | 2015-10-22 |
CL2007002686A1 (es) | 2008-04-18 |
WO2008036540A3 (en) | 2008-05-29 |
US10624882B2 (en) | 2020-04-21 |
US20080161297A1 (en) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062900A1 (es) | Derivados de isoquinolina y de quinazolina utiles como inhibidores de quinasa rho | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR078786A1 (es) | Derivados de la cromenona | |
AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
AR068466A1 (es) | Cianoisoquinolina | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
RS52210B (en) | CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR048346A1 (es) | Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central. | |
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
AR059516A1 (es) | Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas | |
ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |